SNMMI Mid-Winter and ACNM Annual Meeting

Leading molecular imaging and nuclear medicine physicians, radiologists, cardiologists, pharmacists, scientists, lab professionals, and technologists, representing the world's top medical and academic institutions and centers will be attending. 

Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the study presented by a prominent heart failure (HF) specialist during a major cardiology congress in the United States show that autonomic regulation therapy (ART) in patients with moderate to severe chronic HF and impaired heart function is well-tolerated, safe, improves the heart's ability to pump blood, and reduces the frequency and severity of symptoms associated with chronic HF.

October 2, 2015 — Tryton Medical Inc. announced that results of a post hoc analysis of the pivotal Tryton Randomized Clinical Trial (RCT) have been published in the peer-reviewed journal Catheterization and Cardiovascular Interventions (CCI). CCI is the official publication of the Society for Cardiovascular Angiography and Interventions (SCAI).

AtriCure Inc. launched the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety of surgical ablation procedures. This offering adds to the cryoICE family of ablation products which are used in the cryosurgical treatment of cardiac arrhythmias.

AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015, the U.S. Food and Drug Administration (FDA) approved a new 60-mg dosage strength for Brilinta to be used in patients with a history of heart attack beyond the first year.

International Symposium on Endovascular Therapy (ISET)

Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and European investigational device exemption (IDE) clinical trial of the Tack Endovascular System.

Kimihiko Kichikawa, M.D., department of radiology at Nara Medical University in Japan, reported two-year results of the Zilver PTX post-market surveillance (PMS) study at the 2015 Cardiovascular and Interventional Radiology Society of Europe (CIRSE) meeting in Lisbon, Portugal. Kichikawa’s presentation focused on initial target data on lesion revascularization (TLR).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now